Literature DB >> 11336616

Citalopram: a comprehensive review.

B G Pollock1.   

Abstract

Citalopram is a selective serotonin re-uptake inhibitor that has demonstrated antidepressant efficacy in numerous controlled clinical trials. Additional studies have shown that the drug benefits patients with other illnesses that are related in some way to serotonergic dysfunction, including anxiety, panic disorder, obsessive-compulsive disorder, premenstrual dysphoria, alcohol dependence and the behavioural disturbances of dementia. This paper reviews the full spectrum of citalopram's clinical efficacy, as well as its safety and tolerability, in a range of patients.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11336616     DOI: 10.1517/14656566.2.4.681

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  14 in total

1.  Serotonin-, protein kinase C-, and Hic-5-associated redistribution of the platelet serotonin transporter.

Authors:  Ana Marin D Carneiro; Randy D Blakely
Journal:  J Biol Chem       Date:  2006-06-27       Impact factor: 5.157

2.  A population PK model for citalopram and its major metabolite, N-desmethyl citalopram, in rats.

Authors:  Nieves Velez de Mendizabal; Kimberley Jackson; Brian Eastwood; Steven Swanson; David M Bender; Stephen Lowe; Robert R Bies
Journal:  J Pharmacokinet Pharmacodyn       Date:  2015-09-22       Impact factor: 2.745

Review 3.  Citalopram and cardiac toxicity.

Authors:  M J Cooke; W S Waring
Journal:  Eur J Clin Pharmacol       Date:  2012-09-21       Impact factor: 2.953

Review 4.  Imaging genomics applied to anxiety, stress response, and resiliency.

Authors:  Ke Xu; Monique Ernst; David Goldman
Journal:  Neuroinformatics       Date:  2006

Review 5.  PharmGKB summary: citalopram pharmacokinetics pathway.

Authors:  Katrin Sangkuhl; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2011-11       Impact factor: 2.089

6.  Effects of acute treatment with antidepressant drugs on sensorimotor gating deficits in rats.

Authors:  B Pouzet; M Paabøl Andersen; S Hogg
Journal:  Psychopharmacology (Berl)       Date:  2004-08-27       Impact factor: 4.530

7.  Effects of chronic treatment with escitalopram or citalopram on extracellular 5-HT in the prefrontal cortex of rats: role of 5-HT1A receptors.

Authors:  I Ceglia; S Acconcia; C Fracasso; M Colovic; S Caccia; R W Invernizzi
Journal:  Br J Pharmacol       Date:  2004-05-17       Impact factor: 8.739

Review 8.  SSRIs versus non-SSRIs in post-traumatic stress disorder: an update with recommendations.

Authors:  Gregory M Asnis; Shari R Kohn; Margaret Henderson; Nicole L Brown
Journal:  Drugs       Date:  2004       Impact factor: 9.546

9.  Long-term administration of citalopram reduces basal and stress-induced extracellular noradrenaline levels in rat brain.

Authors:  Yukie Kawahara; Hiroshi Kawahara; Fumi Kaneko; Masatoshi Tanaka
Journal:  Psychopharmacology (Berl)       Date:  2007-05-30       Impact factor: 4.530

10.  rac-4-[4-Cyano-2-(hy-droxy-meth-yl)phen-yl]-4-(4-fluoro-phen-yl)-4-hy-droxy-N,N-dimethyl-butanaminium hemifumarate.

Authors:  En-Ju Wang; Guang-Ying Chen
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2011-01-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.